



PROCEEDINGS

Open Access

Application of a nanotechnology antimicrobial spray to prevent lower urinary tract infection: a multicenter urology trial

Wei He¹, Dongmin Wang², Zhangqun Ye¹, Weihong Qian³, Yan Tao³, Xiaofeng Shi³, Ling Liu⁴, Jin Chen⁵, Ling Qiu⁶, Peng Wan⁷, Xiaojun Jia⁸, Xia Li⁹, Caixia Gao¹⁰, Xuexia Ma¹¹, Biyan Wen⁹, Nianzhen Chen¹², Ping Li¹³, Zhengzheng Ren¹⁴, Li Lan¹⁵, Siyi Li¹⁶, Yi Zuo¹⁷, Hua Zhang¹⁸, Liming Ma¹⁸, Yueping Zhang¹⁸, Zhicong Li¹⁹, Weiping Su²⁰, Qing Yang²¹, Qingli Chen²², Xuejing Wang²², Zhenni Ye²³, JP Chen²⁴, Wings TY Loo^{24,25*}, Louis WC Chow²⁵, Adrian YS Yip²⁵, Elizabeth LY Ng²⁵, Mary NB Cheung²⁵, Zhiping Wang^{2†}

From Organisation for Oncology and Translational Research (OOTR) 7th Annual Conference Hong Kong. 13-14 May 2011

Abstract

Background: Catheter-associated urinary tract infection (CAUTI) is a common nosocomial device-associated infection. It is now recognized that the high infection rates were caused by the formation of biofilm on the surface of the catheters that decreases the susceptibility to antibiotics and results in anti-microbial resistance. In this study, we performed an *in vitro* test to explore the mechanism of biofilm formation and subsequently conducted a multi-center clinical trial to investigate the efficacy of CAUTI prevention with the application of JUC, a nanotechnology antimicrobial spray.

Methods: Siliconized latex urinary catheters were cut into fragments and sterilized by autoclaving. The sterilized sample fragments were randomly divided into the therapy and control group, whereby they were sprayed with JUC and distilled water respectively and dried before use. The experimental standard strains of *Escherichia coli* (*E. coli*) were isolated from the urine samples of patients. At 16 hours and 7 days of incubation, the samples were extracted for confocal laser scanning microscopy. A total of 1,150 patients were accrued in the clinical study. Patients were randomized according to the order of surgical treatment. The odd array of patients was assigned as the therapy group (JUC), and the even array of patients was assigned as the control group (normal saline).

Results: After 16 hours of culture, bacterial biofilm formed on the surface of sample fragments from the control group. In the therapy group, no bacterial biofilm formation was observed on the sample fragments. No significant increase in bacterial colony count was observed in the therapy group after 7 days of incubation. On the 7th day of catheterization, urine samples were collected for bacterial culture before extubation. Significant difference was observed in the incidence of bacteriuria between the therapy group and control group (4.52% vs. 13.04%, $p < 0.001$).

Conclusions: In this study, the effectiveness of JUC in preventing CAUTI in a hospital setting was demonstrated in both *in vitro* and clinical studies.

* Correspondence: wtyloo@gmail.com

† Contributed equally

²⁴School of Chinese Medicine, The University of Hong Kong, Hong Kong SAR
Full list of author information is available at the end of the article

Background

Catheter-associated urinary tract infection (CAUTI) is a common nosocomial device-associated infection. Urinary tract infection (UTI) accounts for up to 40% of nosocomial infections and is one of the main types of health-care-associated infections (HAI). About 80% of UTIs are catheter-associated [1,2]. In the United States, approximately 95% of UTIs were associated with the indwelling catheters [3], and interestingly, 15-25% of patients in short-term hospital care need to be inserted with indwelling urinary catheters [4]. Every year, there are more than 5 million patients necessitating catheterization therapy [5] and approximately 1 million patients suffering from CAUTI [6]. The findings of a European study indicated that 5.4% of patients aged 65 or above required the use of an indwelling urinary catheter [7].

CAUTI is a highly common infection and comes with considerable risk. The duration of hospitalization owing to CAUTI increased from 2.4 to 5.4 days in the United States [8]. On average, the costs of diagnosing and treating CAUTI is US\$ 589, excluding extension of hospital costs [9]. Taking into account the expenses of hospitalization, the average cost increases from US\$ 2,836 to 3,803 [10,11]. The Centers for Disease Control and Prevention (CDC) pointed out that UTI leads to deaths of over 13,000 patients every year in the United States [12], indicating a growing medical problem.

It is now recognized that the high infection rates were caused by the formation of biofilm on the surface of the catheters that decreases the susceptibility to antibiotics and results in anti-microbial resistance [8,13,14]. The formation of biofilm as a result of extracellular polysaccharide matrix secretions from microorganisms has been demonstrated in clinical studies. Bacterial biofilm is a special honeycomb-shaped structure that forms a very complex ecosystem; magnification of biofilm will reveal microcolonies under the microscope [15-18]. Organisms with biofilm can withstand shear force, pH changes, and antimicrobial agents, and prevent macrophage phagocytosis [13,19]. The proximity of cells allows more frequent genetic information exchange than other free cells [20]. Therefore, antimicrobial resistance genes and strains can be spread easily. With respect to catheters, the formation of biofilm will protect the pathogenic bacteria residing at the urinary tract from antimicrobial medicine and host immune response [15]. It will then facilitate the growth of bacteria which further complicates the problem of CAUTI [13].

Recent research focused on the development of preventive methods for biofilm formation and changes, including furanone, furacilinum, silver-coated catheters, in addition to other techniques. [21-24]. Johnson *et al.* [21,2] discovered that catheters containing silver hydrogel and nitrofurazone coating have excellent effects of

inhibiting biofilm formation, but no inhibitory effects for *Pseudomonas aeruginosa*. According to the study conducted by CDC, the results of a comparison of patients inserted with silver-coated catheters and standard catheters for one week revealed no difference in bacteriuria prevention [25]. Silver-bearing catheters can decrease the effect of bacteriuria in a week after indwelling. Burton *et al.* [8] discovered the new oPDM-plus-PS (N, N'-(1,2-phenylene) dimaleimide [oPDM]-plus-protamine sulfate [PS]) coating can inhibit *Pseudomonas aeruginosa* and *Staphylococcus epidermidis* adhering to the catheters, but now these coated catheters can only provide short-term CAUTI prevention upon urinary catheter insertion [13]. Recently, Stickler *et al.* [26] revealed that bacteria on the biofilm of catheters produced quorum-sensing signal that can control the genetic expression of forming biofilm. If the signal is blocked, the formation of biofilm can be impeded. For example, the mutant *Pseudomonas aeruginosa* in the absence of quorum-sensing signal was unable to produce a three-dimensional biofilm [27]. An important finding was established regarding iron and the formation of biofilm. Clinical investigations have detected that elements such as iron are necessary nutrients for biofilm formation. The production of catheters without iron is a new development, but it has not been tested in clinical trials [13]. The use of probiotics can also be considered. Trautner *et al.* [28,29] observed that the rates of pathogenic bacterial infection and CAUTI were reduced if the catheters were inoculated with the non-pathogenic *Escherichia coli* (*E. coli*). Although these methods are considerable, there is no conclusive evidence and the cost-effectiveness remains unclear.

The traditional use of JUC applied to the wounds of post-surgery patients has proven to be effective in the hospital and out-patient setting: application of JUC did not result in drug resistance, nor stimulate serious adverse reactions and reduced the average wound healing time of patients [30]. JUC is composed by nano-manufacture technology, with nano-cations on the nano-scale molecular structure produced and then prepared in water-soluble spray [31]. JUC achieves antibacterial action on skin and wound surface by physical mechanisms and can therefore be regarded as a physical antimicrobial agent [31]. Upon application, JUC prevents bacterial growth by forming an invisible, positively charged protective film on the sprayed surface, isolating and eradicating negatively charged pathogenic micro-organisms including bacteria, fungi and viruses [31,32].

There is no effective way to prohibit biofilm formation clinically; therefore, there is still an unmet need for the establishment of a new clinical application. In this study, we performed an *in vitro* test to explore the mechanism of biofilm formation and subsequently conducted a multicenter clinical trial to investigate the efficacy of CAUTI

prevention with the application of JUC, a nanotechnology antimicrobial spray.

Methods

In vitro testing

Bacteria

The experimental standard strains of *E. coli* were isolated from the urine samples of UTI patients at the Second Hospital of Lanzhou University. Bacteria were cultured in Luria-Bertaini broth [33]. The bacterial suspension was prepared and the bacterial concentration was adjusted to 7.4×10^9 CFU/ml.

Preparation of sample fragment

Siliconized latex urinary catheters were cut into sample fragments and sterilized by autoclaving. The sterilized sample fragments were randomly divided between the therapy and control group, with 8 pieces of fragments in each group. The sample fragments were respectively sprayed with JUC and distilled water, and dried before use. The *E. coli* suspension was injected into 24 well plates in which the sample fragments were placed. The plates were then incubated at 37 °C and washed with PBS solution every 48 hours [34]. At 16 hours and 7 days of incubation, the samples were extracted for confocal laser scanning microscopy.

Confocal laser scanning microscopy

The cultured samples were soaked in 1 ml PBS solution. After 50 µg/ml propidium iodide was added, the samples were left for dyeing in a dark area at 4°C for 15 minutes or at room temperature for 30 minutes. The samples were then placed upside down on a glass slide for observing the biofilm formation using laser scanning microscopy [35,36].

Clinical trial

The clinical study commenced in March 2010 and was completed in December 2011. Patients undergoing urological surgery in need of indwelling urethral catheter and more than 7 days of hospitalization were recruited. A total of 1,150 patients (869 male and 281 female), aged from 2 to 82 years, were accrued. Twenty-three hospitals participated in this clinical trial, and every hospital accrued 25 patients each to the control group and therapy group. All patients were operated due to urological diseases, including but not limited to urinary tract stones, tumors, prostatic hyperplasia, ureteral stenosis and hydronephrosis. Indwelling urethral catheter was necessary for patients requiring over 7 days of hospital stay. The midstream urine bacterial culture [15-17] was negative at the time of inclusion in the study. Exclusion criteria of the study included patients with a long-term use of balloon catheter, intermittent self-catheterization, previous treatment of percutaneous paracentetic suprapubic cystostomy and UTI patients. Patients were randomized according to the order of surgical treatment. The odd

array of patients (575 cases) was assigned as the therapy group (the JUC), and the even array of patients (575 cases) was assigned as the control group (normal saline). Patients who were eligible for the trial were explained the nature and purpose of the trial by the investigator, and informed consent was obtained for inclusion in the trial. The Ethics Committee of Tongji Hospital approved the clinical study (Approval Number: 2010006D).

Study design

Therapy group

Prior to the insertion of the catheter into the ureter of the patient at the time of surgery, JUC was sprayed on the surface of the catheter to allow formation of a physical antimicrobial membrane. After surgery, in addition to traditional nursing care, JUC was sprayed onto the skin and mucous membrane around the urethral orifice, the catheter and the drainage tube attachment point. This was done twice a day with 1 ml per spray (approximately 10 sprays) until the catheter was removed on the 7th day.

Control group

The catheter was inserted during surgery. After surgery, conventional nursing care with normal saline was performed until the catheter was removed on the 7th day.

During the study, and according to routine clinical practice, antibiotics were prescribed to patients after surgery. The types, dosage and route of antibiotics prescribed to the patients were carefully and strictly recorded according to the class of antibiotics per institutional guidelines (Table 1).

Class one, class two and class three antibiotics were cumulatively given 521 (40.08%), 572 (44%) and 207 (15.92%) treatment times respectively. There were no restrictions of use for class one antibiotics: they were proven to be safe and effective for long-term clinical application with minimal effects on antimicrobial resistance. The drugs belonging to class one are considered relatively inexpensive antimicrobial agents. Class two antibiotics demonstrated properties of restricted use, with concerned safety, efficacy, and antimicrobial resistance in humans. In comparison, class two drugs were relatively more expensive than the drugs of class one, non-restricted use antibiotics. Class three antibiotics are newly approved, antimicrobial agents with limited safety and efficacy information. There were reported adverse reactions with the use of class three antibiotics. Owing to the concerned safety of class three drugs, they are not recommended for use. Special attention should be made for clinical use to avoid bacterial resistance to antimicrobial agents. Amongst the three classes of antibiotics, class three are relatively more expensive in nature.

The clinical practice on the use of antibiotics differed between all hospitals. A total of 150 patients required the combination use of antibiotics, which were prescribed for

Table 1 Classification of antibiotics used in the clinical trial

Class	Antimicrobial agents	Types	Usage Frequency	Rate of Usage
1	piperacillin, nafcillin, mezlocillin, azlocillin, ticarcillin, mezlocillin, amoxicillin, cefazolin, ceftazidime, cefathiamidine, cefprozil, cefixime, cefotiam, ceftriaxone, cefaclor, Cefonicid sodium, cefamandole sulfate, azithromycin, levofloxacin, ciprofloxacin, Lomefloxacin, enoxacin, gatifloxacin, amikacin, Amikacin' Thiamphenicol, clindamycin	27	521	40.08%
2	ampicillin / sulbactam sodium, timentin / clavulanate, mezlocillin / sulbactam, amoxicillin / clavulanic acid, amoxicillin / sulbactam sodium, piperacillin / sulbactam sodium, cefuroxime sodium, cefmenoxime, cefotaxime sodium, cefpiramide, cefminox, cefodizime, cefpodoxime proxetil, cefetamet pivoxil, cefdinir, aztreonam, latamoxef sodium, ceftioxin sodium, sparfloxacin, moxifloxacin, fleroxacin, antofloxacin hydrochloride, tosufloxacin, etimicin, sisomicin, fusidate sodium, ornidazole	27	572	44%
3	Ceftizoxime, ceftazidime, ceftazidime, cefoperazone, cefoperazone / sulbactam sodium, ceftriaxone / sulbactam sodium, ceftriaxone / sulbactam sodium, cefoperazone / tazobatan, cefepime, cefoselis, imipenem / cilastatin, meropenem, Norvancomycin	13	207	15.92%

0 to 7 days according to the condition of the patient. The percentage use of class one antibiotics in Guangzhou First Municipal People's Hospital and The First Affiliated Hospital of the Sun Yat-sen University was 97.92% and 94.12% respectively, but the use of class two antibiotics was 97.40% in Daping Hospital of the Third Military Medical University. No significant difference was observed in the use of antibiotics between therapy and control groups in each hospital. For example, in the Second Hospital of Xi'an Jiaotong University, class one antibiotics were given to 10 cases in both therapy and control groups, class two antibiotics were given to 12 and 18 cases in treatment and control groups respectively, and class three antibiotics were given to 8 and 6 cases in treatment and control groups respectively. In the General Hospital of Guangzhou Military Command of PLA, class one antibiotics were given to 10 cases in both the therapy and control groups, class two antibiotics were given to 13 and 16 cases in the treatment and control groups respectively, and class three antibiotics were given to 4 and 3 cases in treatment and control groups respectively. Despite the difference in the clinical practice on the use of antibiotics between hospitals, the results were statistically meaningful.

After surgery, the body temperature and UTI symptoms were recorded every day. After 7 days of catheterization, urine samples were collected under aseptic condition for bacterial culture before extubation [37].

Outcome assessment

The collected urine samples with colony count $\geq 10^3$ CFU/ml was considered as CAUTI, based on the quantitative urine culture. [9,38,39].

Statistical analysis

Parameters were compared using SPSS version 14.0. The T-test was used to compare the incidence of CAUTI between groups, where $P < 0.05$ was considered as statistically significant.

Results


In vitro test results

After 16 hours of culture, bacterial biofilm formed on the surface of sample fragment in the control group. The bacterial biofilm was dyed red by propidium iodide fluorescent dye (Figure 1A). In the therapy group, no bacterial biofilm formation was observed on the sample fragments. Only small red dots representing a very small number of free bacteria were observed under microscope (Figure 1B).

After 7 days of culture, in the control group with distilled water, the surface of the sample fragments formed a thick, uniform color, dense and darkly stained layer of bacterial biofilm. Due to bacterial overgrowth, the biofilm was cross-linked to form clumps of bacteria and the surface of the sample fragments was rough and uneven (Figure 2A). The surface of sample fragments in the therapy group formed only a small amount of thin membranous structure with smooth surface and light color. No other abnormality was observed (Figure 2B).

Clinical trial results

Significant difference was not observed in demographics including age, gender, etiology, and geographical distribution between the two groups. On the 7th day of catheterization, urine samples were collected for bacterial culture before extubation. In the therapy group, positive bacterial culture was detected in 26 (4.52%) cases, of which 24 cases were *E. coli*, 1 case was *Enterococcus faecalis* and 1 case was *smooth Candida*. In the control group, bacteriuria was detected in 75 (13.04%) cases, of which 69 cases were *E. coli*, 2 cases were *Enterococcus faecalis*, 2 cases were *Enterococcus cloacae*, 1 case was *Candida albicans* and 1 case was *Pseudomonas aeruginosa*. Detailed results were shown in Table 2. Among all 101 cases of infections, 93 (92.08%) cases were *E. coli* infections, 3 (2.97%) cases were *Enterococcus faecalis*, and 2 (1.98%) cases were *Enterococcus cloacae*. Significant difference was observed in the incidence of



bacteriuria between the control group and control group (4.52% vs. 13.04%, $p < 0.001$).

Discussion

Types of bacteria

UTI is a major nosocomial infection. CAUTI is one of the most common types of bacterial infections [1,2]; ample intestinal bacteria cultivates around the urethra [3,38]. A majority of the short-term CAUTIs were caused by a single strain of bacteria, such as *E. coli*, *Proteus mirabilis* and *Klebsiella pneumoniae*, whereas long-term CAUTI was caused by multiple microorganisms [3,40,41]. Urethra pathogenic *E. coli* is the most common cause of CAUTI which constitutes 50% of hospital-acquired UTIs [3,42]. In our study, similar results were

observed. *E. coli* infection was dominated by 92.08%, while other bacteria such as *Enterococcus faecalis* and *Enterococcus cloacae* constituted a minute proportion of UTIs.

Prevention of catheter-associated infection

Twenty years ago, the U.S. CDC clearly emphasized that hand hygiene, sterile catheterization and closed drainage systems were the necessary elements in preventing CAUTI [43,44]. Recently, the Healthcare-Associated Infections Allied Task Force proposed several frameworks, including infection surveillance, enhancement of education and training in the prevention of CAUTI, the use of appropriate technology for catheter insertion, replacement of indwelling urinary catheter by condoms




Table 2 Comparison of post-operative urinary bacterial culture between the control and therapy group

Groups	Number of Case	Before Surgery	Day 7 after surgery	Types of bacteria					
				<i>Escherichia coli</i>	<i>Enterococcus faecalis</i>	<i>Enterococcus cloacae</i>	<i>Candida albicans</i>	<i>Candida glabrata</i>	<i>Pseudomonas aeruginosa</i>
Therapy	575	0	26 (4.52%)*	24	1	0	0	0	1
Control	575	0	75 (13.04%)	69	2	2	1	0	1

* P<0.001, statistically significant

and intermittent catheterization, immediate removal of the catheter, and other frameworks to prevent the occurrence of CAUTI [43,45,46].

The World Health Organization claimed systemic prophylactic antibiotic, irrigation of bladder, instilling normal saline or antibiotics, sterile drainage bag and other measures are ineffective in preventing the occurrence of CAUTI [1]. The use of anti-microbial drugs, anti-microbial drainage bag and irrigation of bladder can only temporarily reduce the chance of bacteriuria [13]. Furthermore, some studies have shown that the use of soap, skin cleansing foam, povidone iodine or saline in perineal care do not affect the incidence of CAUTI [47]. As for materials of the catheter, the single biological surface coated with silicon, polyurethane, synthetic biomaterials, or hydrogel material, were not proven effective in the prevention of bacterial colonization [5,16].

The formation of biofilm is regarded as one of the major causes of anti-microbial resistance and refractory CAUTI [13]. Therefore, the prevention of biofilm formation has been the research focus toward reducing the incidence of CAUTI. In this study, we investigated the use of new nanotechnology anti-microbial spray JUC, composed of organic silicon quaternary ammonium salt. JUC forms a positively charged film which isolates and kills negatively charged pathogenic micro-organisms including bacteria, fungi and viruses. The physical attraction between the film and the micro-organism would not lead to drug resistance [30].

In the laboratory, the formation of biofilm can be initiated by a small amount of bacteria. The bacteria clump together and form bacterial colonies. It then starts to form a biofilm. When the biofilm matures, it begins to shrink and collapse [48,49]. In the *in vitro* study, the initial stage of biofilm formation was observed at 16 hours of bacterial culture in the control group. After 7 days of incubation, aggregation of bacterial clumps was observed and the surface of sample fragments was unevenly rough, which illustrated the formation of mature biofilm. However, only few free bacteria, represented by red dots under microscope, were also observed in the therapy group. A thin membranous structure was observed which was at a stage between the bacterial colony formation and the initial formation of biofilm. The *in vitro* study clearly

demonstrated that the physical anti-microbial film formed by JUC could prevent biofilm formation for 7 days upon application, which was validated in the clinical study. A significantly lower incidence of CAUTI was observed clinically in the therapy group (4.52%) than in the control group (13.04%), which further confirmed the effectiveness of JUC in the prevention of CAUTI.

Comparison between clinical trials

The pre-operative use of anti-microbial drugs as an effective way for the prevention of bacterial infection is widely accepted [50]. In many clinical trials, prophylactic antibiotics were commonly prescribed for the prevention of infection in catheterized patients [5]. The UTI rate did not exclude the factor of antibiotics use. In Tambyah's study [6], the mean antibiotics use was 1.6 ± 1.7 per catheter-day, and the incidence of CAUTI was 14.9% in the urology department. In the surgical unit, 1,162 patients were catheterized patients after surgery. The onset of CAUTI was 6.4 ± 6.1 catheterized days, and the incidence was 11.9% [6]. In Darouiche's study [51], 124 patients were catheterized in place for 14 days with regular silicone bladder catheters or silicone bladder catheters impregnated with minocycline and rifampin after radical prostatectomy. All patients were given a single parental dose of 1g cefazolin as prophylactic antibiotic before anesthesia. The UTI rates measured 7 days after surgery were 15.2% and 39.7% in patients with regular catheters and medicated catheters respectively. The incidence was much higher than the therapy or control group patients of our study.

Compared to the study of 1,497 patients with an overall incidence of CAUTI of 14.9% by Tambyah *et al.* [6], the incidence of CAUTI was higher than the therapy group (4.52%) and slightly higher than the control group (13.04%) of our study. In Tambyah's study, the patients were catheterized with nitrofurazone-impregnated silicone catheters, silver-polyurethane hydrogel catheters or control catheters and obvious differences were not observed in the incidence of UTI between medicated catheters and control catheters. Despite the different practices of the use of antibiotics between Tambyah's study and our study, it seems the duration and types of post-operative antibiotics were not associated with the

incidence of CAUTI. However, a significantly reduced incidence of CAUTI was observed in the therapy group of our study, indicating that the use of JUC, which was effective in preventing the biofilm formation, could be vital to lowering the incidence of CAUTI.

Conclusions

In the clinical trial, only 4.52% of the patients from the therapy group were diagnosed with CAUTI, compared to 13.04% from the control group. *In vitro* testing also showed no obvious biofilm formation in the therapy group sprayed with JUC after 7 days of bacterial incubation. Biofilm began forming after 16 hours of incubation in the control group. The results from the clinical trial and *in vitro* test demonstrated the effectiveness of JUC in the prevention of CAUTI and formation of biofilm.

Acknowledgements

We express our heartfelt thanks for the strong support of Chinese Medical Association Society of Urology. We are also thankful for the close collaborations with Tongji Affiliated Hospital of Tongji Medical College of the Huazhong University of Science & Technology, the Second Hospital of Lanzhou University, Peking University People's Hospital, the Second Military Medical University (Shanghai Changhai Hospital), the First Affiliated Hospital of the Sun Yat-sen University, the Second Affiliated Hospital of the Sun Yat-sen University, the Third Affiliated Hospital of the Sun Yat-sen University, the Second Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine, the First Affiliated Hospital of Southern Medical University (Nanfeng Hospital), the First Affiliated Hospital of Guangzhou Medical University, General Hospital of Guangzhou Military Command of PLA, Wuhan General Hospital of Guangzhou Military Region, Guangzhou First Municipal People's Hospital, Foshan Hospital of Traditional Chinese Medicine, West China Hospital of the Sichuan University, Daping Hospital of the Third Military Medical University, Xiangya Hospital of the Central-south University, the Second Hospital of Xi'an Jiaotong University, the First Affiliated Hospital of Nanjing Medical University, Nanjing Drum Tower Hospital Affiliated to the Nanjing University Medical School, the Second Affiliated Hospital of Kunming Medical College, Hua'an First Hospital Affiliated to Nanjing Medical University and the Affiliated Hospital of Nantong University. This article has been published as part of *Journal of Translational Medicine* Volume 10 Supplement 1, 2012: Selected articles from the Organisation for Oncology and Translational Research (OOTR) 7th Annual Conference. The full contents of the supplement are available online at <http://www.translational-medicine.com/supplements/10/S1>.

Author details

¹Department of Urology, Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science & Technology, Hubei PRC. ²Institute of Urology, the Second Hospital of Lanzhou University, Lanzhou, PRC. ³Wuhan General Hospital of Guangzhou Military Region, Guangzhou, PRC. ⁴West China Hospital, Sichuan University, Sichuan, PRC. ⁵Daping Hospital, Third Military Medical University, Chongqing, PRC. ⁶The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, PRC. ⁷The Second Military Medical University, Changhai Hospital, Shanghai, PRC. ⁸Peking University People's Hospital, Beijing, PRC. ⁹The Third Affiliated Hospital, Sun Yat-sen University, Guangdong, PRC. ¹⁰The Second Hospital of Xi'an Jiaotong University, Xi'an, PRC. ¹¹The Second Affiliated Hospital, Sun Yat-sen University, Guangzhou, PRC. ¹²Xiangya Hospital of Central-south University, Changsha, PRC. ¹³Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, PRC. ¹⁴Hua'an First Hospital Affiliated to Nanjing Medical University, Jiangsu, PRC. ¹⁵The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, PRC. ¹⁶The Second Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine, Guangzhou, PRC. ¹⁷The First Affiliated Hospital of Southern Medical University (Nanfeng Hospital), Guangzhou, PRC. ¹⁸Affiliated Hospital of

Nantong University, Jiangsu, PRC. ¹⁹Foshan Hospital of Traditional Chinese Medicine, Guangdong, PRC. ²⁰Guangzhou First Municipal People's Hospital, Guangzhou, PRC. ²¹General Hospital of Guangzhou Military Command of PLA, Guangzhou, PRC. ²²The First Affiliated Hospital of Nanjing Medical University, Jiangsu, PRC. ²³The Second Affiliated Hospital of Kunming Medical College, Yunnan, PRC. ²⁴School of Chinese Medicine, The University of Hong Kong, Hong Kong SAR. ²⁵UNIMED Medical Institute, Hong Kong SAR.

Authors' contributions

QC, NC, JC, JPC, CG, WH, XJ, LL, ZL, SL, XL, PL, LL, XM, LM, WQ, LQ, ZR, XS, WS, YT, PW, XW, DW, ZW, BW, QY, ZY, YZ, HZ, YZ equally conducted clinical test planning and performance. LWCC, WTYL, MNBC, AYSY and ELYN participated in the writing of the manuscript.

Competing interests

The authors state they have no competing interests to declare.

Published: 19 September 2012

References

1. Prevention of hospital-acquired infections. A practical guide, 2 2002, WHO/CDS/CSR/EPH/2002.12.
2. Haley RW, Culver DH, White JW, Morgan WM, Emori TG: **The nationwide nosocomial infection rate: a new need for vital statistics.** *AM J Epidemiol* 1985, **121**:159-67.
3. Trautner BW, Darouiche RO: **Catheter-associated infections: pathogenesis affects prevention.** *Arch Intern Med* 2004, **164**:842-85.
4. Johnson JR, Kuskowski MA, Wilt TJ: **Systemic review: Antimicrobial urinary catheters to prevent catheter-associated urinary tract infection in hospitalized patients.** *Ann Intern Med* 2006, **144**:116-26.
5. Maki DG, Tambyah PA: **Engineering out the risk for infection with urinary catheters.** *Emerg. Infect. Dis* 2001, **7**:342-347.
6. Tambyah PA, Maki DG: **Catheter-associated urinary tract infection is rarely symptomatic: a prospective study of 1,497 catheterized patients.** *Arch. Intern. Med* 2000, **160**:678-682.
7. Sorbye LW, Finne-Soveri H, Ljunggren G, Topinkova E, Bernabei R: **Indwelling catheter use in home care; elderly, aged 65+, in 11 different countries in Europe.** *Age Ageing* 2005, **34**:377-381.
8. Burton E, Gawande PV, Yakandawala N, LoVetri K, Zhanel GG, Romeo T, Friesen AD, Madhyastha S: **Antibiofilm activity of GImU enzyme inhibitors against catheter-associated uropathogens.** *Antimicrob Agents Chemother* 2006, **50**:1835-1840.
9. Tambyah PA, Knasinski V, Maki DG: **The direct costs of nosocomial catheter-associated urinary tract infection in the era of managed care.** *Infect Control Hosp Epidemiol* 2002, **23**:27-31.
10. Saint S: **Clinical and economic consequences of nosocomial catheter-related bacteriuria.** *Am J Infect Control* 2000, **28**:68-75.
11. Greene L, Marx J, Oriola S: **Guide to the Elimination of Catheter-Associated Urinary Tract Infections (CAUTIs).** The Association for Professionals in Infection Control and Epidemiology (APIC) Washington, DC; 2008.
12. **Catheter-Associated Urinary Tract Infection (CAUTI) Event.** CDC; 2009.
13. Trautner BW, Darouiche RO: **Role of biofilm in catheter-associated urinary tract infection.** *AM J Infect Control* 2004, **32**:177-183.
14. Costerton JW, Stewart PS, Greenberg EP: **Bacterial biofilms: a common cause of persistent infections.** *Science* 1999, **284**:1318-1322.
15. Donlan RM, Costerton JW: **Biofilms: Survival Mechanisms of Clinically Relevant Microorganisms.** *Clin. Microbiol. Rev* 2002, **15**:167-193.
16. Donlan RM: **Biofilms and device-associated infections.** *Emerg. Infect. Dis* 2001, **7**:277-281.
17. Schaudinn C, Stoodley P, Kainovic A, O'Keefe T, Costerton B, Robinson D, Baum M, Erlich G, Webster P: **Bacterial biofilms, other structures seen as mainstream concepts.** *Microbe* 2007, **2**:231-237.
18. Flemming HC, Neu TR, Wozniak DJ: **The EPS Matrix: The "House of Biofilm Cells".** *J. Bacteriol* 2007, **189**:7945-7947.
19. Costerton J, Geesey G, Cheng K: **How bacteria stick.** *Sci Am* 1978, **238**:86-95.
20. Hausner M, Wuertz S: **High rates of conjugation in bacterial biofilms as determined by quantitative in situ analysis.** *Appl. Environ. Microbiol* 1999, **65**:3710-3713.

21. Johnson JR, Delavari P, Azar M: **Activities of a nitrofurazone-containing urinary catheter and a silver hydrogel catheter against multidrug-resistant bacteria characteristic of catheter-associated urinary tract infection.** *Antimicrob. Agents Chemother* 1999, **43**:2990-2995.
22. Johnson JR, Berggren T, Conway AJ: **Activity of a nitrofurazone matrix urinary catheter against catheter-associated uropathogens.** *Antimicrob. Agents Chemother* 1993, **37**:2033-2036.
23. Tenke P, Kovacs B, Bjerklund Johansen TE, Matsumoto T, Tambyah PA, Naber KG: **European and Asian guidelines on management and prevention of catheter-associated urinary tract infections.** *Int J Antimicrob Agents* 2008, **31**(Suppl 1):S68-78.
24. Kunin CM: **Nosocomial urinary tract infections and the indwelling catheter: what is new and what is true?** *Chest* 2001, **120**:10-12.
25. Gould CV, Umscheid CA, Agarwal RK: **Guideline for prevention of catheter-associated urinary tract infections 2009 (CDC).** *Infect Control Hosp Epidemiol* 2010, **31**:319-326.
26. Stickler D, Morris N, McLean R, Fuqua C: **Biofilms on indwelling urethral catheters produce quorum-sensing signal molecules in situ and in vitro.** *Appl Environ Microbiol* 1998, **64**:3486-90.
27. Davies D, Parsek M, Pearson J, Iglewski B, Costerton J, Greenberg E: **The involvement of cell-to-cell signals in the development of a bacterial biofilm.** *Science* 1998, **280**:295-8.
28. Trautner B, Hull R, Darouiche R: **Escherichia coli 83972 inhibits catheter adherence by a broad spectrum of uropathogens.** *Urology* 2003, **61**:1059-62.
29. Trautner B, Darouiche R, Hull R, Hull S, Thornby J: **Pre-inoculation of urinary catheters with Escherichia coli 83972 inhibits catheter colonization by Enterococcus faecalis.** *J Urol* 2002, **167**:375-379.
30. Zeng Y, Runzhi Deng R, Yeung BH, Loo WTY, Cheung MN, Chen JP, Zhou B, Fu Y, Huang L, Lu M, Wang M: **Application of an antibacterial dressing spray in the prevention of post-operative infection in oral cancer patients: A phase 1 clinical trial.** *African Journal of Biotechnology* 2008, **7**:3827-3831.
31. Li W, Ma X, Peng Y, Cao J, Loo TY, Hao L, Cheung MN, Chow LW, Jin L: **Application of a nano-antimicrobial film to prevent ventilator-associated pneumonia: A pilot study.** *African Journal of Biotechnology* 2011, **10**:1926-193.
32. Wan KA, Ng MY, Wong T: **New horizon on community-acquired methicillin resistant Staphylococcus aureus (CA-MRSA) skin and soft tissue infection: nanotechnology antimicrobial spray.** *Hong Kong Journal of Emergency Medicine* 2011, **18**:432-436.
33. Viana ES, Campos ME, Ponce AR: **Biofilm formation and acyl homoserine lactone production in Hafnia alvei isolated from raw milk.** *Biol Res* 2009, **42**:427-436.
34. Pearson MM, Laurence CA, Guinn SE, Hansen EJ: **Biofilm Formation by Moraxella catarrhalis In Vitro: Roles of the UspA1 Adhesin and the Hag Hemagglutinin.** *Infect Immun* 2006, **74**:1588-1596.
35. Oasgupta MK, Bettcher KB, Ulan RA, Burns V, Lam K, Oossetor JB, Costerton WJ: **Relationship of adherent bacterial biofilms to peritonitis in chronic Ambulatory Peritoneal dialysis.** *Perit Dial Int* 1987, **7**:168-73.
36. Gorman SP, Mawhinney WM, Adair CG, Issoukis M: **Confocal laser scanning microscopy of peritoneal catheter surfaces.** *J Med Microbiol* 1993, **38**:411-7.
37. **Guidelines on Standard Operating Procedures for MICROBIOLOGY – Chapter 19- Urinary Tract Infection.** WHO SEARO; 2006.
38. Saint S, Lipsky Benjamin A: **Preventing Catheter-Related Bacteriuria. Should We? Can We? How?** *Arch Intern Med* 1999, **159**:800-808.
39. Stensballe J, Tvede M, Looms D, Lippert FK, Dahl B, Tønnesen E, Rasmussen LS: **Infection risk with nitrofurazone-impregnated urinary catheters in trauma patients: a randomized trial.** *Ann Intern Med* 2007, **147**:285-293.
40. Vejborg RM, Klemm P: **Blocking of Bacterial Biofilm Formation by a Fish Protein Coating.** *Appl Environ Microbiol* 2008, **74**(11):3551-3558.
41. McTaggart LA, Rigby RC, Elliott TS: **The pathogenesis of urinary tract infections associated with Escherichia coli, Staphylococcus saprophyticus and S. epidermidis.** *J Med Microbiol* 1990, **32**:135-141.
42. Jacobsen SM, Stickler DJ, Mobley HL, Shirtliff ME: **Complicated Catheter-Associated Urinary Tract Infections Due to Escherichia coli and Proteus mirabilis.** *Clin Microbiol Rev* 2008, **21**:26-59.
43. Saint S, Meddings JA, Calfee D, Kowalski CP, Krein SL: **Catheter-associated urinary tract infection and the Medicare rule changes.** *Ann Intern Med* 2009, **150**:877-884.
44. Wong ES: **Guideline for prevention of catheter-associated urinary tract infections.** *Am J Infect Control* 1983, **11**:28-36.
45. Yokoe DS, Mermel LA, Anderson DJ, Arias KM, Burstin H, Calfee DP, Coffin SE, Dubberke ER, Fraser V, Gerding DN, Griffin FA, Gross P, Kaye KS, Klompas M, Lo E, Marschall J, Nicolle L, Pegues DA, Perl TM, Podgorny K, Saint S, Salgado CD, Weinstein RA, Wise R, Classen D: **A compendium of strategies to prevent healthcare-associated infections in acute care hospitals.** *Infect Control Hosp Epidemiol* 2008, **29**(Suppl 1):S12-21.
46. Lo E, Nicolle L, Classen D, Arias KM, Podgorny K, Anderson DJ, Burstin H, Calfee DP, Coffin SE, Dubberke ER, Fraser V, Gerding DN, Griffin FA, Gross P, Kaye KS, Klompas M, Marschall J, Mermel LA, Pegues DA, Perl TM, Saint S, Salgado CD, Weinstein RA, Wise R, Yokoe DS: **Strategies to prevent catheter-associated urinary tract infections in acute care hospitals.** *Infect Control Hosp Epidemiol* 2008, **29**(Suppl 1):S41-50.
47. Jeong I, Park S, Jeong JS, Kim DS, Choi YS, Lee YS, Park YM: **Comparison of Catheter-associated Urinary Tract Infection Rates by Perineal Care Agents in Intensive Care Units.** *Asian Nursing Research* 2010, **4**:142-150.
48. Douglas LJ: **Medical importance of biofilms in Candida infections.** *Rev Iberoam Micol* 2002, **19**:139-143.
49. Xi C, Marks DL, Schlachter S, Luo W, Boppart SA: **High-resolution three-dimensional imaging of biofilm development using optical coherence tomography.** *J Biomed Opt* 2006, **11**:34001.
50. Antibiotic Action Group Aintree Hospitals NHS Trust, Aintree University Hospitals NHS Foundation Trust, The Walton Centre: **Guidelines For Antimicrobial Therapy.**, Eighth 2007.
51. Darouiche RO, Smith JA Jr, Hanna H, Dhabuwalla CB, Steiner MS, Bahaian RJ, Boone TB, Scardino PT, Thornby JI, Raad II: **Efficacy of antimicrobial-impregnated bladder catheters in reducing catheter-associated bacteriuria: a prospective, randomized, multicenter clinical trial.** *Urology* 1999, **54**:976-981.

doi:10.1186/1479-5876-10-S1-S14

Cite this article as: He et al.: Application of a nanotechnology antimicrobial spray to prevent lower urinary tract infection: a multicenter urology trial. *Journal of Translational Medicine* 2012 **10**(Suppl 1):S14.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

